Eric Halioua

Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA.

GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium.

Sopartec SA is the investment and technology valorization arm of Université Catholique de Louvain (UCL) and was founded in 1942. Sopartec SA is headquartered in Louvain-la-Neuve, Belgium.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.

Henogen SA develops and manufactures biopharmaceuticals. The company was founded on November 19, 1999 and is headquartered in Charleroi, Belgium.

Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland.

Certi-Fed SA is an investment holding Belgian company founded in 2007. The private company is based in Brussels, Belgium.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

The European Vaccine Initiative manufactures vaccines. The private company is based in London, UK.

Cliniques Universitaires Saint-Luc operates as a hospital which provides reference care and treats serious, rare or complex diseases of patients. The company was founded on August 23, 1976 and is headquartered in Brussels, Belgium.

develops vaccines to cure disorders of the immune system. Its services include preclinical evaluation, clinical immunomonitoring, technical transfer, consulting and training services, cell, gene, and protein readout development, and clinical biomarker panels validation. The company was founded in 2007 and is headquartered in Gosselies, Belgium.

Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium.

4 for Cells SPRL provides business outsourcing services. The private company is based in Hastière, Belgium. The Belgian company was founded in 2011. François Lesage has been the CEO of the company since 2011.

MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium.

OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium.

Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.

Accessia Pharma SA is a Belgian company that focuses on manufacturing products according to the needs of their clients. The company is based in Herstal, Belgium. The company provides tools and resources to help their clients benefit from economies of scale. Benjamin Boinem has been the CEO of the company since 2015.

AuXin Surgery SA develops, manufactures, and supplies combined medical devices for non-invasive surgery. The private company is based in Ottignies-Louvain-la-Neuve, Belgium. The Belgian company was founded in 2014 by Philippe Capart, Cecile Capart, Herve Capart, Carlo Zini, and Gilles Capart. The CEO is Benoît Verjans.

IRE ELiT SRL is a company based in Fleurus, Belgium that specializes in the fabrication of radiochemical and radiopharmaceutical products, as well as providing radioactivity analysis services. The Belgian company has developed a new platform called RAMSES for real-time radiological analysis. For the past 50 years, IRE has been at the forefront of innovation in healthcare and nuclear medicine services. The company was founded in 2010 and the CEO is Erich Kollegger.

Fluxys SA is an independent energy infrastructure group based in Brussels, Belgium with 1,300 employees. The Belgian company is active in gas transmission and storage, as well as liquefied natural gas terminalling. Fluxys operates 12,000 kilometers of pipeline and liquefied natural gas terminals with a yearly regasification capacity of 29 billion cubic meters. The company's purpose is to contribute to a better society by shaping a bright energy future. Fluxys is committed to transporting hydrogen, biomethane, or any other carbon-neutral energy carrier, as well as CO2, accommodating the capture, usage, and storage of the latter. The company was founded in 2008, and the CEOs are Walter Peeraer and Pascal de Buck.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

Cometsambre SA the recycling of ferrous metals is one of the COMET Group's main activities, performed through Cometsambre SA, and also forms the main axis for development and expansion. The growth of COMETSAMBRE means that they now handle a supply of almost 1 000 000 tones of scrap iron per year, making they the biggest producer of iron and steel industry materials in Belgium. The principles constantly applied in its management, expansion, commercial and operational pro-activity and technological expertise make COMETSAMBRE a leading company in the world of ferrous metal recycling. They are a serious partner, guaranteeing product quality, and respect for environmental standards-technical performance for recycling.

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.

LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.

DNAlytics SA engages in the development of data-driven precision medicine solutions. The firm provides consultancy services; and academic medical, biological, and clinical research laboratories for the pharmaceutical, biotechnology and In-Vitro Diagnostic companies. It also offers software programs unde rthe REED, LiblineaR, jForest, and BLISS brands. The company was founded by Pierre Dupont and Thibault Helleputte in 2012 and is headquartered in Louvain-la-Neuve, Belgium.